India’s Biotechnology Laws and Regulatory Mechanisms

India’s biotechnology sector is regulated through a layered framework that covers genetic engineering, biosafety, drug approvals, biodiversity conservation and seed regulation. The system is designed to balance scientific innovation with public health, environmental safety and statutory oversight.

The Core Legislative and Institutional Framework

• Environment (Protection) Act, 1986: This is the main biosafety law for genetically engineered organisms and related activities.
• Rules, 1989: The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms, Genetically Engineered Organisms or Cells, 1989 provide the operational framework for regulatory control.
• GEAC: The Genetic Engineering Appraisal Committee under the Ministry of Environment, Forest and Climate Change (MoEF&CC) is the apex statutory authority for approving environmental release of genetically modified organisms.
• Regulatory scope: The framework governs release, use, import and storage of regulated biotech materials, especially where environmental or biosafety risks are involved.
• DNA Technology Bill withdrawal: The DNA Technology (Use and Application) Regulation Bill, 2019, which proposed a statutory framework for DNA profiling, was withdrawn from the Lok Sabha in July 2023.
• BRAI Bill lapse: The Biotechnology Regulatory Authority of India (BRAI) Bill, 2013, intended to create a single-window biotechnology regulator, has lapsed without a replacement.

BioE3 Policy and the Bio-RIDE Scheme

• BioE3 Policy: Approved by the Union Cabinet on August 24, 2024, the Biotechnology for Economy, Environment and Employment (BioE3) Policy seeks to build a $300 billion bioeconomy by 2030.
• Focus areas: The policy promotes biomanufacturing across six thematic sectors and aims to link innovation with employment and environmental goals.
• National Biofoundry Network: Launched by the Department of Biotechnology (DBT) and BIRAC in August 2025, it integrates 15 bio-enabler facilities across India to accelerate biomanufacturing.
• BioE3 Cells: These coordinating cells are being established in states to align central policy with regional implementation.
• D.E.S.I.G.N for BioE3 Challenge: This national youth challenge has been launched to support innovation linked to the BioE3 framework.
• Bio-RIDE Scheme: Approved in September 2024, the scheme has an outlay of ₹9,197 crore for FY 2021-22 to FY 2025-26.
• Scheme structure: It merges Biotechnology R&D and Industrial & Entrepreneurship Development with a new Biomanufacturing and Biofoundry component.
• Funding caps: Financial assistance is capped at ₹50 crore for Bio-AI Hubs, ₹65 crore for Biofoundries and ₹75 crore for Biomanufacturing Hubs.

Developments in GM Crops and Genome Editing

• Bt cotton: It remains the only commercially approved GM crop in India since its conditional approval by the GEAC in 2002.
• DMH-11 mustard: In July 2024, a two-judge Supreme Court bench delivered a split verdict on the 2022 environmental release approval of Dhara Mustard Hybrid-11.
• Supreme Court direction: The matter was referred to a three-judge bench, and the court directed the MoEF&CC to formulate a National Policy on GM Crops in consultation with states, experts and farmers.
• Genome-edited rice: In May 2025, India approved its first two genome-edited rice varieties, DRR Dhan 100 (Kamala) and Pusa DST Rice 1, developed using CRISPR-Cas9.
• Regulatory exemption: Site-Directed Nuclease (SDN)-1 and SDN-2 categories of genome-edited plants are exempt from Rules 7 to 11 of the 1989 Rules under the Environment (Protection) Act, 1986.
• Draft Seeds Bill, 2025: Released on November 12, 2025, it is intended to replace the Seeds Act, 1966.
• Seed registration: The draft Bill mandates registration on the SATHI portal for commercial seed varieties, while traditional, farm-saved and farmer varieties remain exempt.

Reforms in Drug Regulation and Biodiversity ABS

• Drugs (Eighth Amendment) Rules, 2026: Notified on June 29, 2026 and effective from July 2, 2026, these rules bring cell-derived products, gene therapeutic products and xenografts under the Centrally License Approving Authority (CLAA) framework.
• Advanced therapies: The amendment strengthens joint central-state regulatory oversight for products such as CAR-T cell therapies and animal tissue-derived heart valves.
• Uniform licensing: The revised framework is meant to standardise approval and licensing for advanced biological therapies.
• Biodiversity Regulations, 2025: Notified on April 29, 2025 under the Biological Diversity (Amendment) Act, 2023.
• Benefit-sharing exemption: AYUSH practitioners and users of cultivated medicinal plants are exempt from benefit-sharing obligations under these regulations.
• ABS slabs: Access and benefit-sharing charges are linked to annual turnover and the ex-factory sale price of the product.

Key Prelims Takeaways

• GEAC location: It functions under MoEF&CC, not under the Ministry of Science and Technology.
• Main biosafety law: The Environment (Protection) Act, 1986 is the core legislation for regulating genetically engineered organisms.
• Only approved GM crop: Bt cotton remains the only commercially approved GM crop in India.
• Genome-editing exemption: SDN-1 and SDN-2 genome-edited plants are exempt from the standard transgenic regulatory process.
• Seed portal: The draft Seeds Bill, 2025 requires commercial seed registration on the SATHI portal.
• Advanced therapies: The CLAA framework now covers cell-derived products, gene therapeutic products and xenografts.
• ABS structure: Biodiversity benefit-sharing is now turnover-linked with specific exemption for the smallest category.